Pecora A L, Bordignon C, Fumagalli L, Radziejewski C, Small T N, Pekle K, O'Reilly R J, Keever C A
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Transplantation. 1991 Feb;51(2):524-31. doi: 10.1097/00007890-199102000-00048.
L-leucyl-L-leucine methyl ester (LLME) is a lysosomotropic agent that in microMolar concentrations has been found to be selectively toxic to human and murine precursor and effector cytotoxic cells, irrespective of their surface membrane phenotype. We describe a new method of synthesis of LLME and evaluate the effects of this preparation on human lymphoid and hematopoietic progenitor cells. The new method of synthesis did not change the previously characterized activities of LLME. Consistent with previous observations, NK effectors, LAK precursors and effectors, and allospecific CTL (aCTL) effectors were completely ablated by treatment with 50-250 microM LLME, while the activities of helper T cells and B cells were preserved after treatments of up to 1000 microM LLME. The effects of LLME treatment on human marrow-derived erythroid, myeloid, and monocyte progenitors have not been previously described. We found that the growth of each of these committed precursors was reduced or eliminated following treatment with 100-250 microM LLME. Admixture of LLME-treated marrow with marrow depleted of T cells and other mature cellular elements resulted in increased growth of myeloid and erythroid colonies suggesting that cells that could provide colony-enhancing activities were preserved. In contrast to previous studies in humans, we found a minority of individuals to have aCTL precursors that were partially resistant to LLME. PBL from 10 of 15 individuals tested showed nearly complete ablation of aCTL precursors following treatment with 375 microM LLME. The remaining 5 individuals demonstrated significant aCTL precursor activity after identical treatment. The resistance to LLME was restricted to aCTL precursors, and neither increasing the dose of LLME nor prolonging the time of treatment completely overcame the resistance. The pattern of susceptibility (sensitive versus resistant) was found to be independent of the degree or type of HLA disparity between responder and stimulator. LLME-treated cultures with and without CTL activity contained a predominance of CD4+ T cells. However, in the subjects tested LLME-resistant aCTL was shown to be CD8+. In vitro priming of aCTL precursors from sensitive individuals did not consistently result in the development of resistance to LLME. These data indicate that further studies are needed to evaluate the effects of LLME on human stem cells and to determine the potential role of resistant aCTL precursors in GvHD prior to application of this technique as a form of selective T cell depletion in humans.
L-亮氨酰-L-亮氨酸甲酯(LLME)是一种溶酶体亲和剂,已发现其在微摩尔浓度下对人和小鼠的前体细胞及效应细胞毒性细胞具有选择性毒性,而不论其表面膜表型如何。我们描述了一种LLME的新合成方法,并评估了该制剂对人淋巴细胞和造血祖细胞的影响。新的合成方法并未改变LLME先前已表征的活性。与先前的观察结果一致,用50 - 250微摩尔LLME处理可使自然杀伤(NK)效应细胞、淋巴因子激活的杀伤细胞(LAK)前体细胞和效应细胞以及同种异体特异性细胞毒性T淋巴细胞(aCTL)效应细胞完全失活,而辅助性T细胞和B细胞在高达1000微摩尔LLME处理后活性得以保留。LLME处理对人骨髓来源的红系、髓系和单核细胞祖细胞的影响此前尚未见报道。我们发现,用100 - 250微摩尔LLME处理后,这些定向祖细胞中的每一种的生长均受到抑制或消除。将经LLME处理的骨髓与去除了T细胞和其他成熟细胞成分的骨髓混合,导致髓系和红系集落的生长增加,这表明能够提供集落增强活性的细胞得以保留。与先前在人体中的研究不同,我们发现少数个体的aCTL前体细胞对LLME具有部分抗性。在测试的15名个体中,有10名个体的外周血淋巴细胞(PBL)在用375微摩尔LLME处理后显示aCTL前体细胞几乎完全失活。其余5名个体在相同处理后表现出显著的aCTL前体活性。对LLME的抗性仅限于aCTL前体细胞,增加LLME剂量或延长处理时间均不能完全克服这种抗性。发现敏感性(敏感与抗性)模式与反应者和刺激者之间HLA差异的程度或类型无关。有或无CTL活性的经LLME处理的培养物中均以CD4 + T细胞为主。然而,在测试的受试者中,对LLME有抗性的aCTL显示为CD8 + 。体外刺激敏感个体的aCTL前体细胞并不一致地导致对LLME产生抗性。这些数据表明,在将该技术作为一种人体选择性T细胞耗竭形式应用之前,需要进一步研究以评估LLME对人干细胞的影响,并确定抗性aCTL前体细胞在移植物抗宿主病(GvHD)中的潜在作用。